Form 4: AngioDynamics SVP Receives Significant Equity Grant

AngioDynamics Inc.'s SVP International, Laura Piccinini, was granted 32,423 restricted stock units and 32,423 performance rights, aligning executive incentives with shareholder returns.

Summary

• Laura Piccinini, SVP International of AngioDynamics Inc. (ANGO), acquired 32,423 shares of common stock in the form of restricted stock units and 32,423 performance rights on July 16, 2025.
• The restricted stock units represent a contingent right to receive one share of Common Stock each and will vest in four equal annual installments, with 25% vesting on July 16, 2026, 2027, 2028, and 2029.
• Each performance right also represents a contingent right to receive one share of Common Stock, with the target number of shares being 32,423.
• The actual number of shares earned from performance rights will range from 0% to 200% of the target, based on total shareholder return relative to a peer group over a three-year performance period.
• A potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group could result in a total potential payout of up to 240% of the target number for performance rights.
• Following these transactions, Laura Piccinini beneficially owns 72,429 shares of Common Stock.
• A Substitute Power of Attorney was executed on January 20, 2025, appointing Lawrence T. Weiss as a substitute attorney-in-fact for Laura Piccinini, superseding previous arrangements.

Sentiment

Score: 7

Explanation: The grant of equity compensation to a senior executive is generally a positive signal, indicating alignment of interests and long-term commitment. The performance-based nature of a significant portion of the grant further enhances this positive sentiment, although the potential for future dilution is a minor consideration.

Positives

• The grant of restricted stock units and performance rights aligns the executive's long-term incentives directly with the company's performance and shareholder value creation.
• The performance rights component, tied to Total Shareholder Return (TSR) relative to a peer group, encourages competitive performance and strategic decision-making.
• The potential for a payout up to 240% of the target for performance rights provides a strong incentive for exceptional performance.

Negatives

• The acquisition of these equity awards at a price of $0, while standard for grants, represents potential future dilution for existing shareholders as the units vest and convert to common stock.

Risks

• The vesting of performance rights is contingent on achieving specific Total Shareholder Return (TSR) metrics relative to a peer group over a three-year period, meaning the actual number of shares received could be zero if performance targets are not met.
• The value of the vested shares is subject to the future market price of AngioDynamics Common Stock, introducing market risk.

Future Outlook

The equity grants are designed to incentivize long-term performance, with restricted stock units vesting annually through July 2029 and performance rights tied to a three-year performance period based on Total Shareholder Return relative to a peer group, with potential payouts ranging from 0% to 240% of the target.

Industry Context

This equity grant is a standard practice in the medical technology and healthcare industry to align executive compensation with long-term company performance and shareholder interests, particularly through performance-based awards like those tied to Total Shareholder Return.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the interests of a key executive with shareholders, potentially leading to improved long-term performance. However, the future vesting of these units will result in some share dilution.
• Employees: The compensation structure for senior management can influence overall compensation philosophy and morale within the company.

Next Steps

• The restricted stock units will vest in four equal annual installments on July 16, 2026, 2027, 2028, and 2029.
• The performance rights will be earned based on Total Shareholder Return relative to a peer group over a three-year performance period, with the outcome determined by the compensation committee.

Key Dates

Keywords

AngioDynamics, ANGO, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Performance Rights, Executive Compensation, Total Shareholder Return, Corporate Governance